tbuckley/cabot-search huggingface dataset:
Abstract 123: Field Accuracy of Paramedic Shock Delivery Using a Filtered ECG Rhythm
Authors: Hill Stoecklein, Andrew Pugh, Michael Stroud, Scott Youngquist
Journal: Circulation (2019)

Introduction: Recognition and rapid defibrillation of shockable rhythms is strongly associated with increased survival from out-of-hospital cardiac arrest (OHCA). The Salt Lake City Fire Department (SLCFD) adopted ECG rhythm filtering technology in 2011, along with a protocol to rapidly defibrillate shockable rhythms without awaiting the end of the 2-minute CPR epoch. Paramedics were also trained to empirically shock asystole, as studies have shown poor agreement in cases of fine and moderate amplitude Ventricular Fibrillation (VF). Hypothesis: We hypothesized that the mandate to shock perceived asystole plus the use of filtering technology would result in high case sensitivity for shockable rhythms at the expense of an unknown frequency of shock delivery to organized rhythms. Methods: Prospectively collected defibrillator data from cardiac arrest cases treated by SLCFD between Dec 2011 and June 2019 were analyzed. Timing of rhythm changes and defibrillation events was manually abstracted using the manufacturer’s review software. The gold standard for rhythm interpretation was post-incident physician interpretation. Results: Paramedics attempted resuscitation in 942 OHCAs. We excluded 41 pediatric cases, 140 cases of BLS or bystander-only AED resuscitation, and 65 cases in which the defibrillator file was unavailable. Overall, 696 adult cardiac arrests with 1,389 shocks delivered were available for analysis. Shocks were delivered to 958 (69%) shockable, 261 (19%) asystole, 158 (11%) PEA, 4 (0.3%) SVT, and 8 (0.6%) unknown underlying rhythms. In 280 cases no shock was delivered despite an initial shockable rhythm in 3 of these cases. Shock delivery case sensitivity was 180/183 (0.98, 95% confidence interval [CI]:0.97-1.0) with false positive proportion of delivered shocks of 158/1,389 (0.11, 95% CI:0.10-0.13) for PEA only and 419/1,389 (0.30, 95% CI:0.28-0.33) for combined PEA and asystole. Neurologically intact (CPC 1-2) overall and Utstein survival rates were 15% and 46% respectively. Conclusions: Using ECG rhythm-filtering technology and an aggressive protocol to defibrillate VF and empirically shock asystole, we demonstrated high case sensitivity for VF at the expense of an 11% rate of shock delivery to underlying PEA.
Impact of Response Shift On Time to Quality of Life Scores Deterioration in Breast Cancer Patients: Is it Time to Move For QOL Recist Criterion?
Authors: Z. Hamidou, T.S. Dabakuyo, F. Guillemin, T. Conroy, M. Velten, D. Jolly, M. Mercier, S. Causeret, J. Cuisnier, F. Bonnetain
Journal: Annals of Oncology (2012)
Hydrocortisone–Ascorbic Acid–Thiamine Use Associated with Lower Mortality in Pediatric Septic Shock
Authors: Eric L. Wald, L. Nelson Sanchez-Pinto, Craig M. Smith, Thomas Moran, Colleen M. Badke, Matthew F. Barhight, Marcelo R. Malakooti
Journal: American Journal of Respiratory and Critical Care Medicine (2020)
A novel cyclic peptide targeting LAG-3 for cancer immunotherapy by activating antigen-specific CD8+ T cell responses
Authors: Wenjie Zhai, Xiuman Zhou, Hongfei Wang, Wanqiong Li, Guanyu Chen, Xinghua Sui, Guodong Li, Yuanming Qi, Yanfeng Gao
Journal: Acta Pharmaceutica Sinica B (2020)

PD-1 and CTLA-4 antibodies offer great hope for cancer immunotherapy. However, many patients are incapable of responding to PD-1 and CTLA-4 blockade and show low response rates due to insufficient immune activation. The combination of checkpoint blockers has been proposed to increase the response rates. Besides, antibody drugs have disadvantages such as inclined to cause immune-related adverse events and infiltration problems. In this study, we developed a cyclic peptide C25 by using Ph.D.-C7C phage display technology targeting LAG-3. As a result, C25 showed a relative high affinity with human LAG-3 protein and could effectively interfere the binding between LAG-3 and HLA-DR (MHC-II). Additionally, C25 could significantly stimulate CD8+ T cell activation in human PBMCs. The results also demonstrated that C25 could inhibit tumor growth of CT26, B16 and B16-OVA bearing mice, and the infiltration of CD8+ T cells was significantly increased while FOXP3+ Tregs significantly decreased in the tumor site. Furthermore, the secretion of IFN-γ by CD8+ T cells in spleen, draining lymph nodes and especially in the tumors was promoted. Simultaneously, we exploited T cells depletion models to study the anti-tumor mechanisms for C25 peptide, and the results combined with MTT assay confirmed that C25 exerted anti-tumor effects via CD8+ T cells but not direct killing. In conclusion, cyclic peptide C25 provides a rationale for targeting the immune checkpoint, by blockade of LAG-3/HLA-DR interaction in order to enhance anti-tumor immunity, and C25 may provide an alternative for cancer immunotherapy besides antibody drugs.
Genetic susceptibility to asthma increases the vulnerability to indoor air pollution
Authors: Anke Hüls, Aneesa Vanker, Diane Gray, Nastassja Koen, Julia L. MacIsaac, David T.S. Lin, Katia E. Ramadori, Peter D. Sly, Dan J. Stein, Michael S. Kobor, Heather J. Zar
Journal: European Respiratory Journal (2020)

Introduction Indoor air pollution and maternal smoking during pregnancy are associated with respiratory symptoms in infants, but little is known about the direct association with lung function or interactions with genetic risk factors. We examined associations of exposure to indoor particulate matter with a 50% cut-off aerodynamic diameter of 10 µm (PM 10 ) and maternal smoking with infant lung function and the role of gene–environment interactions. Methods Data from the Drakenstein Child Health Study, a South African birth cohort, were analysed (n=270). Lung function was measured at 6 weeks and 1 year of age, and lower respiratory tract infection episodes were documented. We measured pre- and postnatal PM 10 exposures using devices placed in homes, and prenatal tobacco smoke exposure using maternal urine cotinine levels. Genetic risk scores determined from associations with childhood-onset asthma in the UK Biobank were used to investigate effect modifications. Results Pre- and postnatal exposure to PM 10 as well as maternal smoking during pregnancy were associated with reduced lung function at 6 weeks and 1 year as well as with lower respiratory tract infection in the first year. Due to a significant interaction between the genetic risk score and prenatal exposure to PM 10 , infants carrying more asthma-related risk alleles were more susceptible to PM 10 -associated reduced lung function (p interaction =0.007). This interaction was stronger in infants with Black African ancestry (p interaction =0.001) and nonexistent in children with mixed ancestry (p interaction =0.876). Conclusions PM 10 and maternal smoking exposures were associated with reduced lung function, with a higher susceptibility for infants with an adverse genetic predisposition for asthma that also depended on the infant's ancestry.
The Role of Tumour Vascular Endothelial Growth Factor (VEGF) and Vascular Endothelial Growth Factor Receptors (VEGFR) Polymorphisms in the Prediction of Clinical Outcome for advanced Hepatocellular Carcinoma Receiving Sorafenib
Authors: L. Faloppi, M. Scartozzi, G. Svegliati Baroni, C. Loretelli, S. De Minicis, A. Mandolesi, M. Bianconi, I. Bearzi, A. Benedetti, S. Cascinu
Journal: Annals of Oncology (2012)
High-throughput analysis of the activities of xCas9, SpCas9-NG and SpCas9 at matched and mismatched target sequences in human cells
Authors: Hui Kwon Kim, Sungtae Lee, Younggwang Kim, Jinman Park, Seonwoo Min, Jae Woo Choi, Tony P. Huang, Sungroh Yoon, David R. Liu, Hyongbum Henry Kim
Journal: Nature Biomedical Engineering (2020)
Thrombomodulin Alfa for Acute Exacerbation of Idiopathic Pulmonary Fibrosis. A Randomized, Double-Blind Placebo-controlled Trial
Authors: Yasuhiro Kondoh, Arata Azuma, Yoshikazu Inoue, Takashi Ogura, Susumu Sakamoto, Kenji Tsushima, Takeshi Johkoh, Kiminori Fujimoto, Kazuya Ichikado, Yasuo Matsuzawa, Takefumi Saito, Kazuma Kishi, Keisuke Tomii, Noriho Sakamoto, Masahiro Aoshima, Jun Araya, Shinyu Izumi, Machiko Arita, Mitsuhiro Abe, Hiroyoshi Yamauchi, Joe Shindoh, Takafumi Suda, Masaki Okamoto, Masahito Ebina, Yoshihito Yamada, Yuji Tohda, Tetsuji Kawamura, Yoshio Taguchi, Hiroshi Ishii, Naozumi Hashimoto, Shinji Abe, Hiroyuki Taniguchi, Jun Tagawa, Koji Bessho, Natsuki Yamamori, Sakae Homma
Journal: American Journal of Respiratory and Critical Care Medicine (2020)

Rationale: Acute exacerbation during the course of idiopathic pulmonary fibrosis causes a poor prognosis. Coagulation abnormalities and endothelial damage are involved in its pathogenesis. Thrombomodulin alfa, a recombinant human soluble thrombomodulin, has anticoagulant and antiinflammatory effects. Several clinical studies have shown that thrombomodulin alfa may improve survival of acute exacerbation.Objectives: To determine the efficacy and safety of thrombomodulin alfa compared with placebo in acute exacerbation of idiopathic pulmonary fibrosis.Methods: This randomized, double-blind placebo-controlled phase 3 study conducted at 27 sites in Japan involved patients with an acute exacerbation of idiopathic pulmonary fibrosis. Subjects were randomized 1:1 to receive placebo or thrombomodulin alfa (380 U/kg/d for 14 d by intravenous drip infusion). All subjects were treated with high-dose corticosteroid therapy. The primary endpoint was the survival proportion on Day 90.Measurements and Main Results: Of the 82 randomized subjects, 77 completed the study and were included in the full analysis set (thrombomodulin alfa, n = 40; placebo, n = 37). The survival proportions on Day 90 were 72.5% (29 of 40) in the thrombomodulin alfa group and 89.2% (33 of 37) in the placebo group, a difference of −16.7 percentage points (95% confidence interval, −33.8 to 0.4%; P = 0.0863). In the safety population (n = 80), bleeding adverse events occurred in the thrombomodulin alfa group (10 of 42; 23.8%) and the placebo group (4 of 38; 10.5%).Conclusions: Thrombomodulin alfa did not improve the 90-day survival proportion. The present results suggest that the use of thrombomodulin alfa for the treatment of acute exacerbation of idiopathic pulmonary fibrosis not be recommended.Clinical trial registered with www.clinicaltrials.gov (NCT02739165).
Response to Chemotherapy in Solitary Fibrous Tumor
Authors: S. Stacchiotti, M. Libertini, E. Palassini, T. Negri, S. Fatigoni, P. Poletti, B. Vincenzi, A.P.I. De Tos, S. Pilotti, P.G. Casali
Journal: Annals of Oncology (2012)
Superior biocompatibility and comparable osteoinductive properties: Sodium-reduced fluoride-containing bioactive glass belonging to the CaO–MgO–SiO2 system as a promising alternative to 45S5 bioactive glass
Authors: S.I. Schmitz, B. Widholz, C. Essers, M. Becker, D.U. Tulyaganov, A. Moghaddam, I. Gonzalo de Juan, F. Westhauser
Journal: Bioactive Materials (2020)

Bioactive glasses (BGs) are promising bone substitute materials. However, under certain circumstances BGs such as the well-known 45S5 Bioglass® (composition in wt%: 45.0 SiO2, 24.5 Na2O, 24.5 CaO, 6.0 P2O5) act cytotoxic due to a strong increase in pH caused by a burst release of sodium ions. A potential alternative is a sodium-reduced fluoride-containing BG belonging to the CaO–MgO–SiO2 system, namely BG1d-BG (composition in wt%: 46.1 SiO2, 28.7 CaO, 8.8 MgO, 6.2 P2O5, 5.7 CaF2, 4.5 Na2O), that has already been evaluated in-vitro, in-vivo and in preliminary clinical trials. Before further application, however, BG1d-BG should be compared to the benchmark amongst BGs, the 45S5 Bioglass® composition, to classify its effect on cell viability, proliferation and osteogenic differentiation of human mesenchymal stem cells (MSCs). Therefore, in this study, the biocompatibility and osteogenic potential of both BGs were investigated in an indirect and direct culture setting to assess the effect of the ionic dissolution products and the BGs' physical presence on the cells. The results indicated an advantage of BG1d-BG over 45S5 Bioglass® regarding cell viability and proliferation. Both BGs induced an earlier onset of osteogenic differentiation and accelerated the expression of late osteoblast marker genes compared to the control group. In conclusion, BG1d-BG is an attractive candidate for further experimental investigation. The basic mechanisms behind the different impact on cell behavior should be assessed in further detail, e.g. by further alteration of the BG compositions.
Clinical significance of Pneumocystis jirovecii DNA detection by real-time PCR in hematological patient respiratory specimens
Authors: José Luis Piñana, Eliseo Albert, María Dolores Gómez, Ariadna Pérez, Juan Carlos Hernández-Boluda, Juan Montoro, Miguel Salavert, Eva María González, Mar Tormo, Estela Giménez, Marta Villalba, Aitana Balaguer-Roselló, Rafael Hernani, Felipe Bueno, Rafael Borrás, Jaime Sanz, Carlos Solano, David Navarro
Journal: Journal of Infection (2020)
Safety and efficacy of nazartinib (EGF816) in adults with EGFR-mutant non-small-cell lung carcinoma: a multicentre, open-label, phase 1 study
Authors: Daniel S-W Tan, Natasha B Leighl, Gregory J Riely, James C-H Yang, Lecia V Sequist, Juergen Wolf, Takashi Seto, Enriqueta Felip, Santiago P Aix, Maud Jonnaert, Chun Pan, Eugene Y Tan, Jinnie Ko, Susan E Moody, Dong-Wan Kim
Journal: The Lancet Respiratory Medicine (2020)
Multi-Cycle High-Dose Chemotherapy with TI-CE Regimen for Patients with Relapsed/Refractory Germ Cell Tumors – a Single Institution Experience
Authors: U. De Giorgi, G. Rosti, B. Kopf, C. Ferrario, G. Papiani, R. De Vivo, A.L. Gentile, F. Fabbri, M. Bragagni, D. Amadori
Journal: Annals of Oncology (2012)
P-0153 Primary Gastointestinal Lymphoma-Incidence, Management and Outcome a Retrospective Study from Tertiary Centre In India
Authors: Peeyush Shukla, Vikas Roshan, Faiz Ansari, Hanish Sharma, Biddhu Mohanti, Minal Bhandari, Pavesh Kumar
Journal: Annals of Oncology (2012)
Randomized Phase II Study of Preoperative Concurrent chemoradiotherapy with or without Induction Chemotherapy with S-1 and Oxaliplatin in Patients with Resectable Esophageal Cancer
Authors: D.H. Yoon, G. Jang, J.H. Kim, Y.-H. Kim, S. Son, J.Y. Kim, S.-I. Park, H.R. Kim, H.-Y. Jung, G.-H. Lee, K.D. Choi, H.J. Song, H.Y. Song, J.H. Shin, K.-J. Cho, S.-B. Kim
Journal: Annals of Oncology (2012)
Care Cycle on Advanced Cancer: Reforming a Value-Based System
Authors: H. Tsukuda, K. Yonesaka, M. Ikeda, M. Otsuka, T. Ozaki, T. Sugiura, Y. Hasegawa, C. Makimura, S. Matsuyama, M. Fukushima, M. Fukuoka
Journal: Annals of Oncology (2012)
Prognostic Role of ERBB Family Receptors, MYC and Mitogen-Activated Protein Kinase (MAPK) in Patients with Early-Stage non Small-Cell Lung Cancer
Authors: V. Ludovini, G. Bellezza, F. Bianconi, R. Chiari, C. Bennati, F.R. Tofanetti, J. Vannucci, F. Puma, A. Sidoni, L. Crinò
Journal: Annals of Oncology (2012)
Putting Drugs at Work Against Brain Metastases in Her2 Positive BC: Results of the Landscape Trial
Authors: T. Bachelot, G. Romieu, C. Cropet, M. Campone, V. Diéras, M. Jimenez, F. Dalenc, E. Le Rhun, C. Labbe-Devilliers
Journal: Annals of Oncology (2012)
DNA damage signalling as an anti-cancer barrier in gastric intestinal metaplasia
Authors: Vaidehi Krishnan, Debbie Xiu En Lim, Phuong Mai Hoang, Supriya Srivastava, Junichi Matsuo, Kie Kyon Huang, Feng Zhu, Khek Yu Ho, Jimmy Bok Yan So, Christopher Khor, Stephen Tsao, Ming Teh, Kwong Ming Fock, Tiing Leong Ang, Anand D Jeyasekharan, Patrick Tan, Khay-Guan Yeoh, Yoshiaki Ito
Journal: Gut (2020)

Objective Intestinal metaplasia (IM) is a premalignant stage that poses a greater risk for subsequent gastric cancer (GC). However, factors regulating IM to GC progression remain unclear. Previously, activated DNA damage response (DDR) signalling factors were shown to engage tumour-suppressive networks in premalignant lesions. Here, we interrogate the relationship of DDR signalling to mutational accumulation in IM lesions. Design IM biopsies were procured from the gastric cancer epidemiology programme, an endoscopic surveillance programme where biopsies have been subjected to (epi)genomic characterisation. IM samples were classified as genome-stable or genome-unstable based on their mutational burden/somatic copy-number alteration (CNA) profiles. Samples were probed for DDR signalling and cell proliferation, using the markers γH2AX and MCM2, respectively. The expression of the gastric stem cell marker, CD44v9, was also assessed. Tissue microarrays representing the GC progression spectrum were included. Results MCM2-positivity increased during GC progression, while γH2AX-positivity showed modest increase from normal to gastritis and IM stages, with further increase in GC. γH2AX levels correlated with the extent of chronic inflammation. Interestingly, genome-stable IM lesions had higher γH2AX levels underscoring a protective anti-cancer role for DDR signalling. In contrast, genome-unstable IM lesions with higher mutational burden/CNAs had lower γH2AX levels, elevated CD44v9 expression and modest promoter hypermethylation of DNA repair genes WRN, MLH1 and RAD52 . Conclusions Our data suggest that IM lesions with active DDR will likely experience a longer latency at the premalignant state until additional hits that override DDR signalling clonally expand and promote progression. These observations provide insights on the factors governing IM progression.
Bispecific and split CAR T cells targeting CD13 and TIM3 eradicate acute myeloid leukemia
Authors: Xin He, Zijie Feng, Jian Ma, Sunbin Ling, Yan Cao, Buddha Gurung, Yuan Wu, Bryson W. Katona, Kienan P. O’Dwyer, Don L. Siegel, Carl H. June, Xianxin Hua
Journal: Blood (2020)
Retrospective Analysis of Cancer-Related Venous Thromboembolism (VTE) at a Single Institution
Authors: T. Shimada, N. Kiyota, Y. Fujiwara, M. Nishimura, Y. Imamura, Y. Funakoshi, H. Tomioka, M. Toyoda, N. Chayahara, K. Yakushijinn, A. Okamura, T. Mukohara, H. Matsuoka, H. Minami
Journal: Annals of Oncology (2012)
Increase of Plasma Adiponectin Levels and Decrease of Pro-Inflammatory Cytokines in Non-Small Cell Lung Cancer Patients Treated with EGFR-TKIS
Authors: K. Umekawa, T. Kimura, T. Suzumura, S. Kudoh, T. Nakai, M. Nagata, K. Matsuura, S. Mitsuoka, N. Yoshimura, K. Hirata
Journal: Annals of Oncology (2012)
“Donation After Circulatory Death” Heart Transplant Is a US First
Authors: Jennifer Abbasi
Journal: JAMA (2020)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Infographic. Roadmap to managing a person with musculoskeletal pain irrespective of body region
Authors: J P Caneiro, Ewa M Roos, Christian J Barton, Kieran O"Sullivan, Peter Kent, Ivan Lin, Peter Choong, Kay M Crossley, Jan Hartvigsen, Anne J Smith, Kevin Wernli, Peter B O’Sullivan
Journal: British Journal of Sports Medicine (2020)

Persistent musculoskeletal (MSK) pain across different body regions is frequently comorbid and shares common biopsychosocial risk profiles for pain and disability.1–3 Biopsychosocial factors require consideration; these include underactivity or overactivity, poor sleep, obesity as well as poor general and psychological health. As such, there is consensus across clinical guidelines on the recommendations …
Integration of Graphene Electrodes with 3D Skeletal Muscle Tissue Models
Authors: Yongdeok Kim, Gelson Pagan‐Diaz, Lauren Gapinske, Yerim Kim, Judy Suh, Emilia Solomon, Jennifer Foster Harris, SungWoo Nam, Rashid Bashir
Journal: Advanced Healthcare Materials (2020)

Abstract Integration of conductive electrodes with 3D tissue models can have great potential for applications in bioelectronics, drug screening, and implantable devices. As conventional electrodes cannot be easily integrated on 3D, polymeric, and biocompatible substrates, alternatives are highly desirable. Graphene offers significant advantages over conventional electrodes due to its mechanical flexibility and robustness, biocompatibility, and electrical properties. However, the transfer of chemical vapor deposition graphene onto millimeter scale 3D structures is challenging using conventional wet graphene transfer methods with a rigid poly (methyl methacrylate) (PMMA) supportive layer. Here, a biocompatible 3D graphene transfer method onto 3D printed structure using a soft poly ethylene glycol diacrylate (PEGDA) supportive layer to integrate the graphene layer with a 3D engineered ring of skeletal muscle tissue is reported. The use of softer PEGDA supportive layer, with a 10 5 times lower Young's modulus compared to PMMA, results in conformal integration of the graphene with 3D printed pillars and allows electrical stimulation and actuation of the muscle ring with various applied voltages and frequencies. The graphene integration method can be applied to many 3D tissue models and be used as a platform for electrical interfaces to 3D biological tissue system.